In this paper, published in the Journal of Biological Chemistry, researchers used Myriad RBM’s services to discover a cytokine signature that was indicative of the in vitro PBMC response to aggregated biotherapeutics. These aggregates initiate immune system activation through specific cell surface receptors and a downstream T-cell response. Identifying a protein signature that describes a biotherapeutic immune response has great potential for helping determine the immunogenicity risk of these compounds.
